Zavegepant is a calcitonin gene related peptide inhibitor which is a new class of drug for acute attack of migraine. It is present in the form of nasal spray for treatment of acute attack of migraine. The objective of study is to evaluate the efficacy , safety and tolerability of this drug for acute attack of migraine. The study was a randomized double blind control trial in which adults (>18 years) with migraine were included in the study. Patients were divided with the help of a web based interactive response system and treated a moderate intensity migraine attack with zavegepant nasal spray 10 mg or placebo. Efficacy was evaluated by relief of symptoms 2 hour after use of nasal spray. 110 patients were randomly divided into 2 groups – group A (57 patients) and group b ( 53 patients). Group A was treated with 10 mg zavegepant nasal spray and group B was given placebo. Group A patients showed the significant relief in symptoms with some showing minor adverse effects such as nausea and crusting in nose. In conclusion zavegepant nasal spray 10 mg is effective for the acute treatment of migraine with good safety profile and tolerability.